Augmentin Dosing for UTI in 88-Year-Old Female with GFR 45
For this patient with CKD Stage IIIa (GFR 45 mL/min), prescribe Augmentin 375 mg (one 250/125 mg tablet) twice daily for 5-7 days, with close monitoring for drug accumulation and adverse effects. 1
Renal Dose Adjustment Rationale
The patient's GFR of 45 mL/min places her at the threshold between CKD Stage IIIa and IIIb, requiring mandatory dose reduction from the standard three-times-daily regimen to prevent amoxicillin-clavulanate accumulation and potential toxicity. 1
For patients with GFR 30-44 mL/min (CKD Stage IIIb), guidelines specifically recommend Augmentin 375 mg twice daily, and this conservative approach is appropriate for your patient given her advanced age (88 years) and borderline renal function. 1
The twice-daily dosing (rather than three-times-daily) accounts for the prolonged elimination half-life of both amoxicillin and clavulanate in reduced renal function, preventing drug accumulation that could lead to crystalluria, neurotoxicity, or hepatotoxicity. 2, 1
Treatment Duration
Standard duration for uncomplicated UTI is 5-7 days, which has demonstrated 63-84% microbiological cure rates in clinical trials of amoxicillin-clavulanate for UTI. 3, 4, 5
For complicated UTI or if the patient has pyelonephritis symptoms, extend treatment to 10-14 days, but maintain the twice-daily dosing schedule given her renal impairment. 6
Critical Monitoring Requirements
Assess renal function (creatinine and GFR) within 48-72 hours of initiating therapy, as elderly patients' renal function may decline during acute illness and antibiotic treatment. 7
Monitor for signs of drug toxicity including rash, pruritus, elevated hepatic transaminases, and gastrointestinal symptoms (nausea, diarrhea), which occur in approximately 20% of patients but are usually mild. 4, 5
If clinical response is inadequate at 48-72 hours, reassess both renal function and consider alternative antibiotics, as further decline in GFR may necessitate additional dose reduction or medication change. 7
Important Clinical Caveats
Avoid increasing to three-times-daily dosing even if clinical response seems suboptimal, as this significantly increases risk of adverse effects in renal impairment without proportional clinical benefit. 2, 1
The higher dose clavulanate regimen (250 mg three times daily) showed increased gastrointestinal intolerance in studies, making the 125 mg formulation twice daily more appropriate for elderly patients. 5
Consider alternative agents (such as ciprofloxacin 250-500 mg every 12 hours or ceftriaxone 1g IV daily) if the patient has severe penicillin allergy or if renal function deteriorates below GFR 30 mL/min during treatment. 7
Temporarily suspend Augmentin if the patient develops intercurrent illness, dehydration, or requires IV contrast administration, as these can precipitate acute kidney injury in vulnerable elderly patients. 2